TrialThe Lancet. Infectious diseases2014

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.

Jared M Baeten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.